Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of […]

Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in […]

The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For […]

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply […]

The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in […]

This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. […]

On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments […]

The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make […]

elglobal.es   In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of […]

Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% […]

In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data […]

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, […]